tbuckley/cabot-search huggingface dataset:
Outcome of 17p Deleted Multiple Myeloma (MM) in the Era of Novel Agents and Tandem Transplantation: A Single Centre Experience
Authors: Gurdeep Parmar, Esther Masih-khan, Eshetu G Atenafu, Donna E. Reece, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, Christine I. Chen
Journal: Blood (2014)
GW26-e0374 Could Central Hemodynamic Indices be the indicator of Orthostatic Hypotension in Chinese Han Nationality population?
Authors: Xiaoping Chen, Kai Liu, Si Wang, Shixi Wan, Yufei Zhou, Pei Pan, Bo Wen, Xin Zhang, Hang Liao, Di Shi, Rufeng Shi
Journal: Journal of the American College of Cardiology (2015)
Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population‐based cohort
Authors: Maa‐Ohui Quarmyne, Wei Dong, Rodney Theodore, Sonia Anand, Vaughn Barry, Olufolake Adisa, Iris D. Buchanan, James Bost, Robert C. Brown, Clinton H. Joiner, Peter A. Lane
Journal: American Journal of Hematology (2016)

The clinical efficacy of hydroxyurea in patients with sickle cell anemia (SCA) has been well established. However, data about its clinical effectiveness in practice is limited. We evaluated the clinical effectiveness of hydroxyurea in a large pediatric population using a retrospective cohort, pre-post treatment study design to control for disease severity selection bias. The cohort included children with SCA (SS, Sβ0 thalassemia) who received care at Children's Healthcare of Atlanta (CHOA) and who initiated hydroxyurea in 2009-2011. Children on chronic transfusions, or children with inadequate follow up data and/or children who had taken hydroxyurea in the 3 years prior were excluded. For each patient healthcare utilization, laboratory values, and clinical outcomes for the 2-year period prior to hydroxyurea initiation were compared to those 2 years after initiation. Of 211 children with SCA who initiated hydroxyurea in 2009-2011, 134 met eligibility criteria. After initiation of hydroxyurea, rates of hospitalizations, pain encounters, and emergency department visits were reduced by 47% (<0.0001), 36% (P = 0.0001) and 43% (P < 0.0001), respectively. Average hemoglobin levels increased by 0.7 g/dl (P < 0.0001). Hydroxyurea effectiveness was similar across gender, insurance types and age, although there was a slightly greater reduction in hospitalizations in younger children. Am. J. Hematol. 92:77-81, 2017. © 2016 Wiley Periodicals, Inc.
A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors
Authors: M. G. Fakih, L. Pendyala, M. J. Egorin, G. Fetterly, I. Espinoza-Delgado, M. Ross, J. Phelan, Z. Kramer, B. Yirinec, R. Diasio
Journal: Journal of Clinical Oncology (2009)

4083 Background: Thymidylate synthase (TS) over-expression is associated with 5-FU resistance. Pre-clinical studies demonstrate that vorinostat down-regulates intra-tumor TS in a dose-dependent fashion and augments 5-FU antitumor activity in xenograft models. We conducted a phase I clinical trial of an intermittent schedule of QD x 3 vorinostat in combination with a fixed dose of fluorouracil (5-FU) and leucovorin (LV) in patients (pts) with refractory solid tumors. Methods: Vorinostat was escalated in a standard 3 x 3 design in combination with a fixed dose of 5-FU and LV (simplified de Gramont regimen, sFULV2). Vorinostat was given QD x 3 on an every-2-week cycle. sFULV2 started on day 2 of vorinostat and consisted of leucovorin 400 mg/m 2 i.v. over 2 hrs followed by 5-FU 400 mg/m 2 bolus and 5-FU 2400 mg/m 2 over 46 hrs. Results: 24 pts were enrolled: Male/Female: 11/13; ECOG 0/1: 6/18; Age: median 60 (range 42–77) yrs. 21 pts had colorectal cancer (CRC), 1 had gastric, 1 had esophageal, and 1 had anal cancer. Vorinostat dose-levels (DL) were 600 mg, 800 mg, 1000 mg, 1200 mg, 1400 mg, 1700 mg, and 2000 mg. Dose-limiting toxicities (DLT), consisting of fatigue and hand-and-foot syndrome (H&amp;F), were seen in 2 of 3 pts at the 2000 mg DL. None of the 6 pts at the 1700 mg DL had a DLT. Cycle 1 grade 3/4 toxicities consisted of thrombocytopenia, GI bleeding, fatigue, and H&amp;F in 2 pts at the 2000 mg DL and a non-DLT G3 diarrhea (lasted &lt;24 hrs) in 1 pt at the 1700 mg DL. Grade 2 nausea, fatigue, and anorexia were common; especially at DL ≥ 1700 mg. Antitumor activity was noted in pts with CRC despite prior refractoriness to 5-FU and failure to oxaliplatin, irinotecan, and cetuximab in all pts. 12/21 CRC pts had a confirmed SD (11) or PR (1). CRC pts had a median PFS of 4 months, a ≥ 6 months PFS rate of 43%, and a ≥ 8 months PFS rate of 33%. Conclusions: The maximum tolerated dose (MTD) of vorinostat in combination with sFULV2 is 1700 mg PO QD x 3 every 2 weeks. This combination is associated with considerable activity in pts with 5-FU-refractory CRC and warrants further investigation. An expanded MTD cohort is accruing to investigate 5-FU-vorinostat PK interaction and intra-tumor TS down-regulation. (This work was supported by a grant from CTEP and the ACS.) No significant financial relationships to disclose.
High-Dose Sequential Chemotherapy Versus a Less Intensive Chemotherapeutic Regimen Followed by Peripheral Blood Progenitor Cell Autografting in Patients with Advanced Hodgkin’s Disease.
Authors: Marcio Nucci, Katia Urago, Eliana A. Miranda, Marcia Delamain, Joao T. Souto Filho, Silvia F. Matte, Carla M. Duarte, Gislaine B. Oliveira, Afonso C. Vigorito, Katia B. Pagnano, Angelo Maiolino, Carmino A. de Souza
Journal: Blood (2005)
Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency.
Authors: Ashraf Z. Badros, Ravi Vij, Thomas Martin, Jeffrey A Zonder, Tina Woo, Zhengping Wang, Susan Lee, Alvin Wong, Ruben Niesvizky
Journal: Blood (2009)
Prevalence of Common Thrombophilia and Antiphospholipid Antibodies in Unexplained Infertility Women Undergoing in Vitro Fertilization (IVF)
Authors: Arie Steinvil, Raanan Raz, Shlomo A. Berliner, David M Steinberg, David Zeltser, David Levran, Orit Shimron, Tal Sella, Gabriel Chodick, Varda Shalev, Ophira Salomon
Journal: Blood (2012)
High Frequency of Concurrent JAK2 V617F Mutation and BCR/ABL Fussion Gene in a Cohort (18/142) of Mexican Patients with MPD
Authors: Rosa Maria Arana Trejo, Veronica A Gonzalez, Israel Saldivar, Beatriz SÃ°nchez, Yolanda Lugo, Jesus Elias Castellanos, Mauricio A Garcia, Jose Ramon Rivas-Llamas, Carlos Valdes Cerda, Gregorio Ignacio Ibarra
Journal: Blood (2012)
German translation and content validation of the OSTRC Questionnaire on overuse injuries and health problems
Authors: A Hirschmüller, K Steffen, K Fassbender, B Clarsen, R Leonhard, L Konstantinidis, N P Südkamp, E J Kubosch
Journal: British Journal of Sports Medicine (2016)

Objective The aim of this study was to translate, culturally adapt and validate the Oslo Sports Trauma Research Centre (OSTRC) Questionnaire on Health Problems into the German context. Methods A slightly modified back-translation method was used to translate the questionnaire. Validation was done in 24 high-level Paralympic athletes followed over 20 consecutive weeks. Results The translated version of the questionnaire showed a very high internal consistency and good test–retest reliability (Cronbach's α 0.92, intraclass correlation coefficient 0.91). Additionally, we observed high acceptance and compliance from our cohort of athletes, whose mean weekly response rate was 91.5%. Overall, 114 training days were lost because of illness or injury within the 20 weeks and, on average, 5 athletes per week (20.8%) reported health problems. Conclusions This study demonstrates that the translated German version of the OSTRC Questionnaire is a reliable and valid tool with high internal consistency for the medical monitoring of German athletes. The OSTRC-G now offers the opportunity for a continued surveillance of high-level German athletes.
<i>The BMJ</i>launches ninth medical awards
Authors: Nigel Hawkes
Journal: BMJ (2016)

Nigel Hawkes explains how to enter and talks to some previous winners

The annual search for excellence in healthcare has begun once more with the opening of nominations for the ninth BMJ Awards, the competition in which the best initiatives from across the UK are invited to compete for the prestigious recognition.

This year, as last, there are 15 entry categories covering the whole of medicine from bench to bedside, not forgetting that the way services are planned and delivered is the key to providing effective care. Past winners represent the best that doctors and the NHS can achieve, with tough times putting an ever greater value on innovation and cost-effectiveness.

Some awards—such as those for primary care, cardiology, cancer, education and innovation—are included every year, while permutation of the many other possible categories aims to ensure that over time all specialties get their …
NOV-002 plus carboplatin in platinum-resistant ovarian cancer
Authors: C. N. Krasner, M. V. Seiden, R. T. Penson, M. Roche, D. L. Kendall, J. Young, U. A. Matulonis, L. Pereira, S. T. Berlin
Journal: Journal of Clinical Oncology (2008)

5593 Background: Platinum remains the single most effective drug for the treatment of epithelial ovarian cancer; however with relapse and re-treatment most patients eventually become resistant to these drugs. Response rates to salvage chemotherapy in this population is 10–20%, with PFS typically < 8 weeks in 4th line. One mechanism of platinum resistance is thought to be mediated by changes in the cellular redox potential. Oxidized glutathione (GSSG), the active component of NOV-002, regulates the intracellular redox state via the glutathione (GSH) pathway. This study aims to determine tolerabilty, response rate and PFS to NOV-002 with carboplatin in women with platinum resistant ovarian, tubal or peritoneal cancer. Methods: NOV-002 is given by IV bolus on lead-in day -1 at cycle 1, and on day 1 at subsequent cycles, followed by Carboplatin AUC 5. NOV-002 is then continued via daily SC injection, with 28 day cycles. Patients must be platinum refractory/resistant, with measurable disease and ≤ 3 prior lines. Fifteen patients are accrued in the first stage of the trial; if ≥ 2 responses, 10 additional patients will be accrued. Results: Stage I accrual is complete. Patients were heavily pretreated with 11/15 having received 3 prior lines. Toxicity was mild-moderate with no grade 4 toxicity. There was no febrile neutropenia. The most common toxicities were nausea and fatigue, as well as abdominal pain and bowel obstruction thought to be related to underlying disease. To date, there is 1 PR, 7 SD and 5 PD, with 1 patient off-trial for patient discretion. PFS is 14 weeks. Treatment and evaluation are ongoing, with the possibility of accrual to the second stage if another PR is seen. Conclusions: Patients tolerated this regimen extremely well, with most toxicity attributable to carboplatin alone. The PFS was longer than expected, with a significant proportion of these platinum resistant patients achieving clinical benefit with prolonged stable disease. Updated results will be available. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Novelos
P0717 : The presence of a PNPLA3 (rs738409) single nucleotide polymorphism (SNP) is not associated with increased risk for fibrosis, portal hypertension, and hepatic steatosis in HIV/HCV-coinfected patients
Authors: B. Scheiner, M. Mandorfer, P. Schwabl, B.A. Payer, M.C. Aichelburg, K. Grabmeier-Pfistershammer, A. Stättermayer, P. Ferenci, M. Trauner, M. Peck-Radosavljevic, T. Reiberger
Journal: Journal of Hepatology (2015)
GW26-e1253 Apelin and APLN single nucleotide polymorphisms and combined hypertension and central retinal artery stenosis in a Chinese population
Authors: Huirong Lin, Fan Lin, Pengli Zhu, Feng Huang, Qiuxia Huang, Qiaowei Li, Zhonghai Gao, Fanli Chen
Journal: Journal of the American College of Cardiology (2015)
A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC0808): Final analysis for survival.
Authors: Hiroshi Tamagawa, Hiroyuki Uetake, Megumi Ishiguro, Nobuyuki Mizunuma, Yusuke Kinugasa, Izumi Mochizuki, Tetsuya Hamaguchi, Junichi Hasegawa, Kenji Katsumata, Keiichiro Ishibashi, Yutaka Ogata, Yasumasa Takii, Mitsuru Ooshiro, Tatsuo Kagimura, Kenichi Sugihara
Journal: Journal of Clinical Oncology (2016)

704 Background: TRICC0808 trial is a phase II trial to evaluate the liver resection rate and safety after mFOLFOX6 + bevacizumab therapy for liver-only metastasis that is unsuitable for upfront resection (H2 and H3) from colorectal cancer. Primary endpoint was the R0 resection rate, which was reported to be 44.4% (Ann Surg Oncol 22: 908-915, 2015). Final analysis of TRICC0808 was performed (February 16, 2015 data fixation). Methods: Forty six patients were registered and OS was analyzed for 45 patients (FAS). In 24 cases with liver resection after protocol chemotherapy, RFS, recurrence rate and recurrence patterns were analyzed. Results: The1, 2 and 3 year OS rate in FAS from the starting date of the chemotherapy was 91.1%, 68.9%, 44.0%, respectively, with 2.80 years of MST. The 3 year OS rate in 31 patients with liver resection including resection after additional chemotherapy was 61.3% with 3.59 years of MST, which was better than 0% of the 3 year OS rate with 1.75 years of MST in patients without liver resection. In 24 who underwent liver resection after 6 cycles of protocol chemotherapy, the 1, 2 and 3 year RFS rate was 29.2%, 12.5%, 8.3%, respectively, with 3.07 years of MST. The recurrence rate for 20 patients with R0 liver resection was 80%, and 100% in those with R1 and R2 liver resection. In the 20 patients with R0 liver resection, the 3 year OS rate of 16 patients with technically resectable liver metastasis at registration and 4 with technically unresectable tumors was 53.6% and 50.0%, respectively. Conclusions: The present final analysis of TRICC0808 trial disclosed good OS in the patients with liver resection, though the large population of the patients recurred afterward. The results were concordant with those of other reported trials for liver metastasis which is unsuitable for upfront resection. Liver resection was thought to be effective for liver metastasis which converted from unresectable to resectable after chemotherapy. Clinical trial information: UMIN000010209.
GW26-e0186 Triptolide inhibits angiotensin II induced cardiac fibroblasts proliferation by down-regulating TGF-β1/Smad3 pathway
Authors: Jian Chen, Mao Liu, James Yeh, Wenyi Tang, Guangyi Tan, Zhijuan Zhou, Xiufang Lin, Wei Wu
Journal: Journal of the American College of Cardiology (2015)
Capecitabine/cisplatin doublet in antracycline and taxane pre-treated patients with metastatic breast carcinoma
Authors: B. Oksuzoglu, H. Abali, N. Ozdemir, B. Budakoglu, M. Hayran, N. Zengin
Journal: Journal of Clinical Oncology (2007)

1093 Background: Treating heavily pretreated metastatic breast cancer patients is challenging. To evaluate the activity and toxicity of the combination of capecitabine and cisplatin (CapCisp) in antracycline and taxane pretreated metastatic breast carcinoma (MBC) patients was the aim of our study. Methods: Thirty-three female MBC patients, 20 to 61 years of age (median; 41) were included in the study. Patients received Cap 2x1000 mg/m 2 on days 1–14, and Cisp 60 mg/m 2 on day 1, repeated every 3 weeks. In the case of disease control without intolerable toxicity, single agent Cap was continued. Results: Infiltrative ductal carcinoma was the most common histology (88%). In 23 patients with assigned histological grade, 13% had grade 1, 48% grade 2, and 39% grade 3 disease. Estrogen receptor (ER), Progesteron receptor (PR), and c-ErbB2 were positive in 39%, 63%, and 42%, respectively. All patients were pretreated with antracycline and taxane on an adjuvant or palliative basis before CapCisp chemotherapy. Altogether were given 154 courses of CapCisp chemotherapy (range; 1–8 courses per patient, median; 5 courses). Disease control rate was 82% (complete response, n: 1; partial response, n:16, stable disease, n: 10, progressive disease, n: 6). Eleven patients continued with single agent Cap (median; 4, range; 3–6 cycles). Grade 1 and 2 nausea/vomiting (66.7%) and fatigue (60.6%) were the most frequently observed side effects. Grade 3 neutropenia was observed in 4 patients (12.1%). Median follow-up was 9.5 months or until death. Median duration of response was 5.1 months (3.2–6.9, %95 CI). Median time to disease progression was 6.3 months (3.8–8.8, %95 CI). Fifteen patients died, and median survival was 11.5 months (6.9–16.1, 95% CI). Conclusion: CapCispl doublet has an encouraging antitumor activity with acceptable and manageable toxicity in antracycline and taxane pretreated metastatic breast carcinoma patients. No significant financial relationships to disclose.
Dual role of p21waf1/cip1 in effects of oxaliplatin (L-OHP) against colon cancer cells in p53 dependent and independent pathway
Authors: T. Hata, H. Yamamoto, M. Ikeda, M. Yasui, I. Seshimo, O. Takayama, H. Hukunaga, M. Ohue, M. Sekimoto, M. Monden
Journal: Journal of Clinical Oncology (2004)

3143 Backgrounds: L-OHP, an active agent for colorectal carcinoma (CRC) is a platinum derivative such as Cisplatin, but its mechanism in antitumor activity is different from Cisplatin. The aim of this study was to investigate the mechanism of L-OHP on cell growth inhibition in terms of p53 status and its down stream effector, p21waf1/cip1 in the CRC cell lines. Methods: p53 wild type cell lines, HCT116, and p53 mutant cell lines, DLD1 and SW480 were subjected to L-OHP for 48 hours to find out IC50. After 48-hour-exposure of L-OHP (IC50), expression of a cell cycle-related factor, p21waf1/cip1, was examined by western blot analysis. Flowcytometric analysis of these cell lines was performed after L-OHP exposure. Results: IC50 of L-OHP in HCT116, DLD1, and SW480 were 0.4, 9.1, and 2.1 μM, respectively, and maximam growth inhibitiory effect on DLD1 was 40% or less even the dose of L-OHP was increased up to 50μM. suggesting p53 status may enhance L-OHP activity. In p53 wild type cell lines, p21waf1/cip1 expression was enhanced by western blot analysis, and increase in G0-G1 phase fraction and decrease in S phase fraction were observed after 12h exposure (G1 arrest pattern) by flowcytometric analysis. In contrast, p21waf1/cip1 expression was decreased, and rapid decrease in G1 phase fraction and increase in S phase was observed after 12h or 24h exposure of L-OHP (G2 arrest pattern) in the p53 mutant type cell lines. Although mRNA expression level of p21waf1/cip1 was not decrease after L-OHP exposure, protein expression was decreased. This decrease in protein expression was inhibited by Clasto-Lactacystin β-lactone, proteasome inhibitor in HCT116 and SW480 cell lines. Conclusion: The antitumor mechanisms of L-OHP were 1) enhancement of expression of p21waf1/cip1 via p53, and 2) direct degradation of p21waf1/cip1 independent of p53. No significant financial relationships to disclose.
Scottish court gives go-ahead to minimum alcohol pricing
Authors: Anne Gulland
Journal: BMJ (2016)

The drinks industry in Scotland has been urged to accept a ruling that a minimum price for a unit of alcohol is legal. The Court of Session in Edinburgh ruled on 21 October that the Scottish parliament had acted in its powers when it passed a bill implementing a minimum price of 50p (€0.56; $0.61) for a unit.

The Scotch Whisky Association, alongside other bodies representing the alcohol industry, has waged a legal battle against the bill since it was passed in …
GW26-e5379 Short-term Peri-procedural Common Doses (Double-Dose vs Usual-dose) of Atorvastatin for Prevention of Contrast-Induced Acute Kidney Injury and Long-term Outcomes in Patients with Different High CRP Levels undergoing Coronary Angiography or Percutaneous Coronary Intervention
Authors: Yong Liu, Wei Guo, Nianjin Xie, Yuanhui Liu, Hualong Li, Dengxuan Wu, Yingling Zhou, Chongyang Duan, Shiqun Chen, PingYan Chen, Ning Tan, Guang Li, Jiyan Chen
Journal: Journal of the American College of Cardiology (2015)
Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations
Authors: Matthew Kaufman, Xiao J. Yan, Emanuela M. Ghia, Donna Neuberg, Laura Z. Rassenti, Kostas Stamatopoulos, Paolo Ghia, David G Oscier, Frederic Davi, Richard Rosenquist, Chrysoula Belessi, Zadie Davis, Andreas Agathangelidis, Neil Kay, John C. Byrd, Jennifer R Brown, Kanti R. Rai, Thomas J. Kipps, Nicholas Chiorazzi
Journal: Blood (2011)
Detection and Characterization of Plasma Cell and B Cell Clones in Patients with Systemic Light Chain Amyloidosis Using Flow Cytometry
Authors: Stefan Schönland, Ute Hegenbart, Christoph Kimmich, Katarina Lisenko, Dirk Hose, Hartmut Goldschmidt, Anna Jauch, Anthony D. Ho, Michael Hundemer
Journal: Blood (2014)
Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.
Authors: Hani Hassoun, Lilian Reich, Virginia M. Klimek, Tarun Kewalramani, Madhav Dhodapkar, Lisa Drake, Rachel Zimman, Cyrus V. Hedvat, Teruya-Feldstein Julie, Fleisher Martin, Daniel A. Filippa, Stephen D. Nimer, Raymond L. Comenzo
Journal: Blood (2004)
Cost of chemotherapy-related febrile neutropenia
Authors: D. Weycker, J. Malin, A. Glass, G. Oster
Journal: Journal of Clinical Oncology (2006)

6068 Background: Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy that typically necessitates hospitalization. While the costs of FN have been reported to be substantial, previous studies may have underestimated these costs due to failure to account for follow-on care. Methods: A retrospective cohort study was undertaken using a US healthcare claims database. The source population included adult cancer patients who received a course of chemotherapy between 2001 and 2003. For each such patient, each unique cycle of chemotherapy was identified, and patients who developed FN within these cycles were further identified based on hospitalization for neutropenia, fever, and/or infection. Patients with FN in a given cycle (“cases”), starting with the first, were matched–on tumor type, number of cycles, chemotherapy characteristics, and propensity score–to those not experiencing FN in that cycle (“controls”), regardless of occurrence of FN in subsequent cycles; once matched, patients were removed from their respective pools. FN-related healthcare charges–including inpatient, outpatient, and drug treatment for neutropenia, fever, and infection–were tallied for each such pair of patients from the cycle day on which cases developed FN through the last chemotherapy cycle. Healthcare charges were used as a proxy for costs, as the latter were unavailable. Results are reported as means and 95% confidence intervals. Results: The study population consisted of 746 patients; 38% had breast cancer, 21% had lung cancer, and 11% had non-Hodgkin’s lymphoma. Cases and controls were similar in terms of baseline characteristics. FN-related charges totaled $40,928 (95%CI $28,783-$62,586) among cases versus $3,933 ($2,890-$5,119) for controls, a difference of $36,995 ($25,283-$58,776). Non-FN-related charges were similar in the two groups ($32,774 [$28,587-$36,061] vs. $32,253 [$29,248-$36,066]). Care subsequent to initial hospitalization accounted for $9,872 (or 27%) of the higher FN-related charges among cases. Conclusions: Costs of care during chemotherapy are twofold higher among patients who develop FN; follow-on care represents more than one-quarter of the difference. [Table: see text]
Use of Reduced Intensity Conditioning (RIC) Regimens Are Associated with a Better Outcome with Sibling Donors Transplants in Older Patients (&gt; 50 years) with Acute Myeloid Leukemia (AML)
Authors: Biju George, Ian Kerridge, Gillian Huang, David J Gottlieb, Mark Hertzberg, Ken Bradstock
Journal: Blood (2008)